Compare Sterling Biotech with Torrent Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STERLING BIOTECH vs TORRENT PHARMA - Comparison Results

STERLING BIOTECH     Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

TORRENT PHARMA 
   Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STERLING BIOTECH TORRENT PHARMA STERLING BIOTECH/
TORRENT PHARMA
 
P/E (TTM) x -0.4 54.1 - View Chart
P/BV x 0.0 6.5 0.2% View Chart
Dividend Yield % 0.0 0.8 -  

Financials

 STERLING BIOTECH   TORRENT PHARMA
EQUITY SHARE DATA
    STERLING BIOTECH
Dec-13
TORRENT PHARMA
Mar-18
STERLING BIOTECH/
TORRENT PHARMA
5-Yr Chart
Click to enlarge
High Rs111,550 0.7%   
Low Rs31,144 0.3%   
Sales per share (Unadj.) Rs26.8354.7 7.6%  
Earnings per share (Unadj.) Rs-15.040.1 -37.3%  
Cash flow per share (Unadj.) Rs-5.564.2 -8.5%  
Dividends per share (Unadj.) Rs014.00 0.0%  
Dividend yield (eoy) %01.0 0.0%  
Book value per share (Unadj.) Rs54.9273.1 20.1%  
Shares outstanding (eoy) m267.87169.22 158.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.33.8 6.8%   
Avg P/E ratio x-0.533.6 -1.4%  
P/CF ratio (eoy) x-1.321.0 -6.1%  
Price / Book Value ratio x0.14.9 2.6%  
Dividend payout %034.9 0.0%   
Avg Mkt Cap Rs m1,862227,897 0.8%   
No. of employees `0001.414.7 9.2%   
Total wages/salary Rs m54711,353 4.8%   
Avg. sales/employee Rs Th5,303.34,083.0 129.9%   
Avg. wages/employee Rs Th403.8772.3 52.3%   
Avg. net profit/employee Rs Th-2,959.0461.3 -641.4%   
INCOME DATA
Net Sales Rs m7,18160,021 12.0%  
Other income Rs m432,988 1.4%   
Total revenues Rs m7,22363,009 11.5%   
Gross profit Rs m94713,493 7.0%  
Depreciation Rs m2,5434,086 62.2%   
Interest Rs m4,3773,085 141.9%   
Profit before tax Rs m-5,9319,310 -63.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-1,9242,529 -76.1%   
Profit after tax Rs m-4,0076,781 -59.1%  
Gross profit margin %13.222.5 58.7%  
Effective tax rate %32.427.2 119.5%   
Net profit margin %-55.811.3 -493.8%  
BALANCE SHEET DATA
Current assets Rs m14,33552,623 27.2%   
Current liabilities Rs m49,80952,022 95.7%   
Net working cap to sales %-494.01.0 -49,296.1%  
Current ratio x0.31.0 28.5%  
Inventory Days Days403120 337.3%  
Debtors Days Days17176 223.9%  
Net fixed assets Rs m55,43285,016 65.2%   
Share capital Rs m268846 31.7%   
"Free" reserves Rs m13,93545,376 30.7%   
Net worth Rs m14,70146,222 31.8%   
Long term debt Rs m9,47841,115 23.1%   
Total assets Rs m73,988142,432 51.9%  
Interest coverage x-0.44.0 -8.8%   
Debt to equity ratio x0.60.9 72.5%  
Sales to assets ratio x0.10.4 23.0%   
Return on assets %0.56.9 7.2%  
Return on equity %-27.314.7 -185.8%  
Return on capital %-6.414.2 -45.3%  
Exports to sales %25.90-   
Imports to sales %0.20-   
Exports (fob) Rs m1,860NA-   
Imports (cif) Rs m12NA-   
Fx inflow Rs m1,86014,580 12.8%   
Fx outflow Rs m253,600 0.7%   
Net fx Rs m1,83510,980 16.7%   
CASH FLOW
From Operations Rs m1,7198,942 19.2%  
From Investments Rs m-3,148-47,070 6.7%  
From Financial Activity Rs m1,42634,174 4.2%  
Net Cashflow Rs m-3-3,655 0.1%  

Share Holding

Indian Promoters % 33.9 71.5 47.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 7.0 -  
FIIs % 9.9 12.6 78.6%  
ADR/GDR % 16.9 0.0 -  
Free float % 39.3 8.8 446.6%  
Shareholders   21,482 26,511 81.0%  
Pledged promoter(s) holding % 55.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STERLING BIOTECH With:   DIVIS LABORATORIES  WOCKHARDT  VENUS REMEDIES  FRESENIUS KABI ONCO.  GLENMARK PHARMA  

Compare STERLING BIOTECH With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Higher; Telecom and Energy Stocks Gain the Most(09:30 am)

Asian share markets are lower today as Chinese and Hong Kong shares fall. The Shanghai Composite is off 0.4% while the Hang Seng is down 0.7%.

Related Views on News

TORRENT PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 36.3% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 36.3% YoY). Sales on the other hand came in at Rs 20 bn (up 5.9% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 32.5% (Quarterly Result Update)

Jul 25, 2019 | Updated on Jul 25, 2019

For the quarter ended June 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 32.5% YoY). Sales on the other hand came in at Rs 20 bn (up 8.0% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 166.7% (Quarterly Result Update)

May 22, 2019 | Updated on May 22, 2019

For the quarter ended March 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 166.7% YoY). Sales on the other hand came in at Rs 19 bn (up 7.8% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 324.1% (Quarterly Result Update)

Jan 31, 2019 | Updated on Jan 31, 2019

For the quarter ended December 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 324.1% YoY). Sales on the other hand came in at Rs 21 bn (up 38.9% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 12.3% (Quarterly Result Update)

Nov 5, 2018 | Updated on Nov 5, 2018

For the quarter ended September 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 12.3% YoY). Sales on the other hand came in at Rs 19 bn (up 32.5% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

More Views on News

Most Popular

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

The Smartest Stock to Buy for 2020(Profit Hunter)

Nov 14, 2019

Small-cap stocks are selling at bargain prices today and are poised to generate a lot of wealth in 2020 and beyond...

Why Moody's Rating Downgrade is a Strong Sign to Buy Stocks(The 5 Minute Wrapup)

Nov 8, 2019

Investors who took cues from Moody's rating downgrade in 1992 and 2002 created some of the biggest wealth of their lifetime.

A Trade that Could Generate Profits for Decades

Nov 14, 2019

India's #1 trader is back on the Investor Hour. Vijay Bhambwani talks to us about his super-profitable trading system and shares with us his #1 long term trade. Listen in...

The One Trade I'm Most Bullish on Now

Nov 12, 2019

A highly specific trade to potentially triple your money in just three months. You won't find this information anywhere else!

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

STERLING BIOTECH SHARE PRICE


Nov 5, 2018 (Close)

TRACK STERLING BIOTECH

  • Track your investment in STERLING BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STERLING BIOTECH

STERLING BIOTECH 5-YR ANALYSIS

COMPARE STERLING BIOTECH WITH

MARKET STATS